AskAt received a notice of allowance dated April 7, 2021 of a use patent for its EP4 receptor antagonist in the treatment of NASH-associated liver cancer. The notice was issued by the China National Intellectual Property Administration (CNIPA), in connection with Chinese Patent Application No. 201780004254.2 (Filing Date: November 2, 2017). In addition to China, the use patent has been granted in Canada, Europe, Japan, Mexico, and the U.S.